Flyer

Journal of Neurology and Neuroscience

  • ISSN: 2171-6625
  • Journal h-index: 18
  • Journal CiteScore: 4.35
  • Journal Impact Factor: 3.75
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor (SJIF)
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Systemic inflammation and neurodegenerative disease

4th International Conference on NEUROLOGY AND NEUROIMMUNOLOGY
September 18-19, 2017 | Dallas, USA

Marcella Reale

University â�?�?G. Dâ�?�?Annunzioâ�?, Italy

Posters & Accepted Abstracts: J Neurol Neurosci

Abstract:

Low-grade inflammatory state is a pathological feature of a wide range of chronic conditions such as neurodegenerative diseases, including Alzheimerâ�?�?s disease, Parkinsonâ�?�?s disease, amyotrophic lateral sclerosis, and multiple sclerosis. The association between inflammation and chronic conditions is widely recognised, and since inflammation inducers may be generated in a diseasespecific manner, the issue of causality and the degree to which inflammation contributes and serves as a risk factor for the development of disease is not fully clarified. Communication between the systemic immune system and the central nervous system (CNS) is a critical component of the inflammatory response, and there is evidence for convergence in the mechanisms responsible for the sensing, transduction, and amplification of inflammatory processes that result in the production of neurotoxic mediators. Several studies have suggested that low-grade peripheral systemic inflammation is associated with increased cognitive decline, and that increased risk of developing Alzheimer disease (AD) may be associated with increased systemic inflammation. Increased levels of inflammatory proteins have been found in the brains and plasma samples of patients with dementia. Proinflammatory cytokines, chemokines and prostaglandins promote neuronal death and plus a role in immune to brain communication by activating the central innate immune response, including microglial cells. Recently, the ability of the nervous system to modulate the cytokine production in the immune system was studied; and the so called â�?�?cholinergic anti-inflammatory pathwayâ�? is responsible of the brainimmune system interface. Knowledge about the cholinergic antiinflammatory pathway as a specific regulator of cytokine responses makes it possible to consider the crosstalk between the CNS and the immune system. Thus, keeping in mind the role of the cholinergic system in inflammation, in addition to the proinflammatory cytokines, the cholinergic agents may be considered as new and interesting therapeutic tools in the pharmacological treatments that may have relevance in neurodegenerative diseases.